🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Wanbury Limited WANBURY NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.wanbury.com

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

READ MORE ›
₹255.95
+1.41% 1Y

Market & Price

Market Cap
₹894.27 Cr
Current Price
₹255.95
High / Low (52W)
₹265.75 / ₹252.40
Beta
-

Valuation

Stock P/E
13.39
Industry PE
35.51
Forward P/E
-
PEG Ratio
-
Book Value
₹18.09
Price to Book
14.15
P/S
2.40
EV/EBITDA
-
Dividend Yield
-

Profitability & Returns

ROCE
28.35%
ROE
-
ROA
-
Profit Margin
-25.90%
Op Margin
5.49%
EPS (Latest Qtr)
₹6.27
EPS (TTM)
₹19.12

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
₹517.67 Cr
Current Assets
₹238.56 Cr
Working Capital
₹37.52 Cr

Ownership

Promoter Holding
51.19%
Chg in Prom Hold
-
FII / Inst Holding
2.07%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
₹371.93 Cr
EBITDA
₹-74.38 Cr
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
₹3.49 Cr
Gross Margin
48.25%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
9.29%
Profit 5Y
245.39%
Revenue (YoY)
-19.20%
Earnings (YoY)
-

PROS

  • Healthy ROCE of 28.4%.
  • Profit CAGR of 245.4% over 5 years.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 WANBURY Wanbury Limited NSEPHARMA 255.95 13.39 ₹894.27 Cr - 28.35% - 9.29% 245.39%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,794.20 37.47 ₹4.30 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,655.50 68.67 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,572.20 71.63 ₹1.55 L Cr 0.85% 9.05% 16.99% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,493.00 62.93 ₹1.22 L Cr 0.24% 19.79% 21.50% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,383.30 28.78 ₹1.12 L Cr 0.94% 14.86% 11.74% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,105.90 22.08 ₹1.11 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,276.00 24.83 ₹1.06 L Cr 0.63% 14.22% 11.83% 10.96% -1.67%
9 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,273.30 19.53 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --172.00 Cr163.18 Cr160.06 Cr162.45 Cr164.58 Cr
Cost of Revenue --84.32 Cr75.35 Cr67.06 Cr68.80 Cr65.30 Cr
Gross Profit --87.68 Cr87.84 Cr93.00 Cr93.65 Cr99.27 Cr
Operating Expenses --61.43 Cr67.04 Cr70.93 Cr70.70 Cr72.65 Cr
Operating Income --26.25 Cr20.80 Cr22.08 Cr22.95 Cr26.62 Cr
EBITDA --31.47 Cr24.79 Cr25.98 Cr26.86 Cr26.45 Cr
Interest Expense --9.04 Cr7.54 Cr7.12 Cr7.26 Cr8.06 Cr
Pretax Income --19.05 Cr13.61 Cr15.16 Cr15.87 Cr15.17 Cr
Tax Provision ---1.20 Cr11.53 L-1.93 L10.61 L-6.53 Cr
Net Income --20.26 Cr13.49 Cr15.18 Cr15.76 Cr21.70 Cr
Diluted EPS --5.983.954.584.516.27

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -498.18 Cr574.48 Cr599.51 Cr650.27 Cr
Cost of Revenue -309.02 Cr310.14 Cr294.47 Cr276.51 Cr
Gross Profit -189.15 Cr264.34 Cr305.04 Cr373.76 Cr
Operating Expenses -177.29 Cr207.13 Cr242.04 Cr281.32 Cr
Operating Income -11.86 Cr57.21 Cr63.01 Cr92.44 Cr
EBITDA -23.49 Cr98.55 Cr79.91 Cr104.09 Cr
Interest Expense -21.39 Cr29.18 Cr36.95 Cr29.98 Cr
Pretax Income --10.29 Cr56.34 Cr29.55 Cr59.80 Cr
Tax Provision -10.90 L38.10 L-97.94 L-6.33 Cr
Net Income --10.40 Cr55.96 Cr30.53 Cr66.13 Cr
Diluted EPS 25.21-3.1816.898.98-

Compounded Sales Growth

5 Years:9.29%
1 Year:-19.20%

Compounded Profit Growth

5 Years:245.39%
1 Year:-

Stock Price Performance

1 Year:+1.41%
6 Months:-
3 Months:-
1 Month:-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -303.52 Cr343.12 Cr413.92 Cr517.67 Cr
Current Assets -123.79 Cr158.61 Cr193.44 Cr238.56 Cr
Cash & Equivalents -1.49 Cr3.40 Cr4.06 Cr1.61 Cr
Inventory -21.99 Cr36.02 Cr37.68 Cr50.63 Cr
Receivables -68.98 Cr88.76 Cr114.16 Cr143.28 Cr
Total Liabilities -336.34 Cr315.18 Cr354.65 Cr373.22 Cr
Current Liabilities -320.03 Cr210.70 Cr174.61 Cr201.04 Cr
Long Term Debt -082.00 Cr160.29 Cr147.15 Cr
Total Debt -108.58 Cr115.80 Cr176.91 Cr224.37 Cr
Total Equity --32.82 Cr27.94 Cr59.27 Cr144.45 Cr
Shares Outstanding -3.27 Cr3.27 Cr3.28 Cr3.49 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -19.80 Cr4.70 Cr26.20 Cr31.53 Cr
Investing Cash Flow --8.84 Cr-16.63 Cr-51.17 Cr-56.40 Cr
Financing Cash Flow --31.99 Cr13.87 Cr25.63 Cr22.42 Cr
Capital Expenditure --12.63 Cr-17.42 Cr-49.03 Cr-59.61 Cr
Free Cash Flow -7.17 Cr-12.73 Cr-22.82 Cr-28.08 Cr
Net Change in Cash --21.03 Cr1.94 Cr66.04 L-2.45 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -38.0%46.0%50.9%57.5%
Operating Margin % -2.4%10.0%10.5%14.2%
Net Margin % --2.1%9.7%5.1%10.2%
ROE % -31.7%200.3%51.5%45.8%
ROCE % --71.9%43.2%26.3%29.2%

Shareholding Pattern

Insiders
51.19%
Institutions
2.07%
Public Float
4.24%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WANBURY

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space